

[191] NOVEL METABOLIC IMMUNO-ONCOLOGY DRUGS FOR SKIN CANCER AND SOLID TUMORS

Oren M. Becker¹, ¹ President and Ceo

- **Investment Rational**

Vidac is a clinical-stage oncology company developing novel drugs targeting metabolic immuno-oncology processes in cancer. Lead product, VDA-1102, is in Phase 2 for actinic keratosis (AK; early cutaneous squamous cell carcinoma) with data in mid-2017. Phase 3 is to start in 1H 2018. VDA-1102 is also being developed for a variety of solid tumors.

- **Business Strategy**

AK is a prevalent early-stage of skin cancer (60M people in US; age-related incidence-rate; \$7B market size). Vidac is developing VDA-1102 ointment for AK under an FDA IND. Following Phase 2 POC we plan to develop the drug to an NDA and to co-market it. A second product, injectable VDA-1102 for solid tumors, will be developed through POC.

- **Core Technology**

Cancer cells, and activated immune cells, undergo metabolic reprogramming from OXPHOS to glycolysis, expressing HK2 in that process. Vidac's novel small-molecule modulators of the VDAC/HK2 interface trigger apoptosis in cancer cells (without affecting the surrounding tissue) and stimulate the immune response. Vidac is developing a pipeline of highly selective, efficacious anti-cancer drugs (NCEs), using a precision medicine approach (HK2 levels).

- **Product Profile/Pipeline**

VDA-1102 ointment is a topical treatment for AK. It is developed under an FDA IND (Phase 2 data in mid-2017; Phase 3 start in early-2018). NDA is expected in 2020. The drug is a first-in-class treatment with sales potential exceeding \$1B. In addition, an injectable formulation of VDA-1102 for solid tumors is expected to begin clinical development in 2018.

- **What's Next?**

VDA-1102 ointment: Phase 2 topline data in mid-2017, followed by an End-of-Phase-2 meeting with FDA by YE 2017, and start of Phase 3 studies in 1H 2018.

VDA-1102 injectable: Preclinical development and pre-IND meeting in 2017. Clinical trials start in 2018.

Financing: Planned for 2H 2017.